This activity is sponsored by PTCE and supported by educational grants from Daiichi Sankyo, Inc and Seattle Genetics, Inc.

Speaker: Allison Butts, PharmD, BCOP, UK Healthcare

Program Description 
Up to 25% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2). The growing availability of targeted therapies with new mechanisms against HER2 has offered patients additional options and improved outcomes. Determining HER2 status based on current guideline-recommended testing is critical to patient-specific therapy selection. It is imperative that oncology care providers be familiar with the optimal sequencing of therapy based on guideline recommendations and nuances of uses for different agents. Despite improved treatment outcomes, there are multiple adverse effects associated with HER2-targeted therapies. This activity will prepare oncology care professionals to identify and manage adverse effects as well as individualize treatment for patients receiving therapies for HER2+ metastatic breast cancer.

Target Audience: Oncology pharmacists, pharmacy technicians, physicians, and nurses

Type of Activity: Knowledge 

Educational Objectives: 
At the completion of this activity, pharmacists, physicians, and nurses will be able to:   

•    Recognize the role and usage of biomarker testing for HER2+ BRCA and how testing results impact therapy

•    Review approved and emerging HER2-targeted agents and combination treatment strategies as well as their roles in evolving guideline recommendations in the treatment of HER2+ metastatic BRCA

•    Discuss the adverse effects of and appropriate management strategies associated with HER2-targeted agents and combination treatment strategies to optimize therapy and patient outcomes

At the completion of this activity, pharmacy technicians will be able to: 

•    Recognize the role and usage of biomarker testing for HER2+ BRCA and how testing results impact therapy

•    Review approved and emerging HER2-targeted agents and combination treatment strategies in the treatment of HER2+ metastatic BRCA

•    Discuss the adverse effects of and appropriate management strategies associated with HER2-targeted agents to optimize therapy and patient outcomes

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (1.0 CEU) under the ACPE universal activity numbers 0290-0000-20-264-L01-P and 0290-0000-20-264-L01-T. The activity is available for CE credit on October 23, 2020.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education 
(ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education™. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this live activity for a maximum of 
3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3 Contact Hours. Instructions for Completing the Activity and Receiving CPE Credit to receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. Credit must be requested no later than December 23, 2020. CE credit will not be issued after this date.